UBS Group Trims Humana (NYSE:HUM) Target Price to $250.00

Humana (NYSE:HUM) had its target price trimmed by UBS Group from $380.00 to $250.00 in a research report sent to investors on Friday, Benzinga reports. The brokerage currently has a neutral rating on the insurance provider’s stock.

Other equities research analysts have also issued research reports about the company. Leerink Partners lowered Humana from an outperform rating to a market perform rating and lowered their price objective for the stock from $400.00 to $250.00 in a research report on Wednesday, October 2nd. JPMorgan Chase & Co. increased their target price on shares of Humana from $332.00 to $396.00 and gave the stock a neutral rating in a research note on Wednesday, August 21st. Leerink Partnrs cut Humana from a strong-buy rating to a hold rating in a report on Wednesday, October 2nd. Piper Sandler lowered Humana from an overweight rating to a neutral rating and dropped their price objective for the company from $392.00 to $274.00 in a report on Thursday. Finally, Oppenheimer reduced their target price on Humana from $400.00 to $280.00 and set an outperform rating for the company in a research note on Thursday. One analyst has rated the stock with a sell rating, sixteen have given a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of Hold and an average price target of $357.24.

Humana Stock Performance

Shares of HUM opened at $240.03 on Friday. The stock has a 50-day moving average of $337.70 and a two-hundred day moving average of $342.89. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66. The stock has a market cap of $28.92 billion, a P/E ratio of 14.95, a P/E/G ratio of 2.44 and a beta of 0.50. Humana has a one year low of $213.31 and a one year high of $530.54.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, topping the consensus estimate of $5.89 by $1.07. The company had revenue of $29.54 billion for the quarter, compared to the consensus estimate of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period last year, the firm earned $8.94 EPS. As a group, research analysts predict that Humana will post 16.01 EPS for the current year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be issued a $0.885 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.54 annualized dividend and a dividend yield of 1.47%. Humana’s dividend payout ratio is presently 22.04%.

Institutional Trading of Humana

Hedge funds and other institutional investors have recently modified their holdings of the stock. CarsonAllaria Wealth Management Ltd. grew its position in Humana by 111.4% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after acquiring an additional 39 shares during the period. Hantz Financial Services Inc. purchased a new position in shares of Humana during the 2nd quarter worth $35,000. Family Firm Inc. acquired a new stake in shares of Humana during the 2nd quarter worth about $37,000. Hollencrest Capital Management purchased a new stake in Humana in the 2nd quarter valued at about $40,000. Finally, Riverview Trust Co acquired a new position in Humana in the second quarter valued at about $44,000. 92.38% of the stock is owned by institutional investors and hedge funds.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.